Loading clinical trials...

NeuroControl of Nicotine Dependence | Clinical Trials | Clareo Health

RECRUITINGNA

NeuroControl of Nicotine Dependence

Neuronavigated Non-invasive Brain Stimulation for Nicotine Dependence.

NCT06347055•University of Missouri-Columbia

Summary

The purpose of the study is to examine the effects of continuous theta burst stimulation (cTBS) on different forms of cognitive control in adults who smoke cigarettes, and to determine if the location where cTBS is delivered may help smokers reduce or quit smoking. Participation in the study will take 3-weeks over 4 visits, with a total time commitment of approximately 12 hours.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Nicotine Dependence as measured by: Smoke ≥ 8 cigarettes/day for ≥ 2 yrs, expired carbon monoxide (CO) concentration of ≥ 10 ppm, positive urine cotinine test and FTND score ≥ 3 Or ≥ 15 uses of electronic cigarette/day for ≥ 1 year, positive urine cotinine test, and PS-ECDI score ≥ 3
•2. English Fluency
•3. Functional Vision (with corrective lenses as needed)

Exclusion Criteria

•1. Use of psychotropic and antiepileptic medications in the last month
•2. Presence of an untreated illness or serious medical condition
•3. History of major neurological illness
•4. Contraindication to TMS (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for \>15 min., implanted electronic device, metal in the head) or MRI.
•5. Any use of substances that lower seizure threshold.
•6. Current or past psychosis
•7. Electroconvulsive therapy in the past 6 months
•8. Unstable cardiac disease or hypertension, severe renal or liver insufficiency, or sleep apnea
•9. BAC greater than 0.0.
•10. Positive urine pregnancy test
+1 more criteria

Locations (1)

Health Neuroscience Center

Columbia, Missouri, United States

Key Dates

Start Date

October 1, 2024

Primary Completion Date

March 25, 2030

Completion Date

April 30, 2030

Last Updated

October 1, 2024

Enrollment

ESTIMATED participants

Conditions

Nicotine Dependence

Interventions

Repetitive Transcranial Magnetic Stimulation (rTMS)

DEVICE

Contacts

Brett Froeliger, PhD

CONTACT

573-882-4785 froeligerb@health.missouri.edu

Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

NCT01036581

Drug AbuseNicotine Dependence

View study

RECRUITINGNA

Behavioral Intervention for Youth to Promote Vaping Cessation

NCT06765291

VapingVaping Teens+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 1, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

NeuroControl of Nicotine Dependence

Inclusion Criteria

Exclusion Criteria

Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

Behavioral Intervention for Youth to Promote Vaping Cessation

tDCS Plus Varenicline for Smoking Cessation

Neurobehavioral Mechanisms Linking Childhood Adversity to Increased Risk for Smoking

Beta-Adrenergic Modulation of Drug Cue Reactivity

Multimodal Neuroimaging Genetic Biomarkers of Nicotine AddictionSeverity